21 "colon cancer" clinical trials found.
-
A Phase 1b/2 Randomized Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
The goal of the study is to find out if a new drug called LBL-007, given in combination with other drugs called tislelizumab, bevacizumab, and ...
-
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
You can participate in this study if you are diagnosed with cancer of the colon or rectum and your cancer progressed after or intolerant to ... -
EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a study to see if a new treatment called A2B530 is safe and effective for people with certain types of cancer that have ...
-
A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.
You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The ... -
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...
-
A Phase I First-In-Human Multicenter Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
The purpose of the study is to determine the safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic ... -
KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
This study will focus on two types of cancer: non-small cell lung cancer and colorectal cancer. The purpose of the study is to find out ...
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
The purpose of the study is to determine and evaluate the safety, tolerability, and preliminary efficacy of oral LY3537982 as monotherapy and as part of ... -
A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
This study is for adults who have advanced solid tumors that lack a certain enzyme called methylthioadenosine phosphorylase (MTAP). This study is split into two ...